Begin main content

Aripiprazole as an Adjunct to Anti-depressants for Major Depressive Disorder: Clinical Effectiveness, Cost-effectiveness, and Guidelines

Last updated: May 4, 2016
Project Number: RA0846-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Reference List
Result type: Report

Question

1.  What is the clinical efficacy of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments?

2.  What is the cost-effectiveness of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments?

3.  What are the evidence-based guidelines for the use of aripiprazole for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments?

Key Message

Three systematic reviews with meta-analyses, two randomized controlled trials, and two evidence-based guidelines were identified regarding the use of aripiprazole as an adjunct to antidepressants for the treatment of patients with major depressive disorder who have had an inadequate response to prior antidepressant treatments.